癌症中的外osomal circRNAs:对治疗耐药性和生物标志物的影响
Zhengjun Lin1, Yuqiao Ji1, Jian Zhou2
1Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China; Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, People's Republic of China.
Cancer letters
|May 29, 2023
概括
外体体中的循环RNAs (circRNAs) 是癌症治疗耐药性的关键驱动因素. 针对这些外体环RNAs提供了一个有希望的策略,以克服治疗失败并改善癌症患者的治疗结果.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 癌症治疗耐药性是治愈治疗的主要障碍.
- 循环RNAs (circRNAs) 是稳定的,在外基因组中发现的非编码RNA.
- 外体circRNAs可以影响癌症的进展和治疗反应.
研究的目的:
- 审查外体circRNAs调解对各种癌症疗法的耐药性的机制.
- 探索外体环RNAs作为生物标志物和药物点的治疗潜力.
- 讨论未来的前景和挑战,以向外体circRNAs用于癌症治疗.
主要方法:
- 关于circRNAs,外体和癌症治疗耐药性的研究的文献综述.
- 对外体circRNA参与化疗,向治疗,免疫治疗和放射治疗耐药性的分子机制的分析.
- 对外体circRNAs临床应用的当前研究的综合.
主要成果:
- 异常表达的外体环RNA与对多种癌症治疗的耐药性有关.
- 外体环RNAs可以在癌细胞之间转移,影响它们的行为.
- 这些分子在癌症的扩散,迁移和免疫逃避中发挥作用.
结论:
- 外体circRNAs代表了一种重要的驱动癌症治疗耐药性的机制.
- 向外体环RNA是一种潜在的策略,可以逆转耐药性并提高治疗疗效.
- 需要进一步的研究,以充分利用外体环RNAs作为生物标志物和瘤学中的治疗点.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Overview of Exosomes
2.8K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.8K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K


